Group 1 | Group 2 | Group 3 | Group 4 | p-value | |
---|---|---|---|---|---|
n=126 | n=121 | n=133 | n=128 | ||
DAS ≤2.4, (%)† | 79 | 76 | 84 | 76 | 0.5 |
DAS <1.6, (%)† | 49 | 56 | 57 | 47 | 0.5 |
DAS <1.6 drug free, %† | 18 | 19 | 17 | 15 | 0.9 |
Still on initial treatment step, %† | 29 | 22 | 45 | 66 | <0.001 |
Mean HAQ over 8 years‡ | 0.69 | 0.71 | 0.63 | 0.57 | <0.05* |
IFX current use, (%)† | 21 | 10 | 13 | 24 | 0.06 |
Lost to follow-up, n (%)‡ | 41 (33) | 43 (36) | 47 (35) | 30 (23) | 0.1 |
Missing data, no. | 8 | 12 | 9 | 4 | |
SHS progression, median (mean)† year 0-8 | 3.0 (14.6) | 4.3 (13.9) | 2.0 (8.5) | 2.0 (8.3) | 0.6 |
†Completers analysis, ‡intention to treat. *LMM: group 2 vs 4, p<0.05, group 1 vs 4, p=0.055, all other, p>0.05.